PMID- 22924465
OWN - NLM
STAT- MEDLINE
DCOM- 20130423
LR  - 20240406
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Print)
IS  - 1472-8222 (Linking)
VI  - 16
IP  - 12
DP  - 2012 Dec
TI  - Targeting disease through novel pathways of apoptosis and autophagy.
PG  - 1203-14
LID - 10.1517/14728222.2012.719499 [doi]
AB  - INTRODUCTION: Apoptosis and autophagy impact cell death in multiple systems of 
      the body. Development of new therapeutic strategies that target these processes 
      must address their complex role during developmental cell growth as well as 
      during the modulation of toxic cellular environments. AREAS COVERED: Novel 
      signaling pathways involving Wnt1-inducible signaling pathway protein 1 (WISP1), 
      phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), beta-catenin and mammalian 
      target of rapamycin (mTOR) govern apoptotic and autophagic pathways during 
      oxidant stress that affect the course of a broad spectrum of disease entities 
      including Alzheimer's disease, Parkinson's disease, myocardial injury, skeletal 
      system trauma, immune system dysfunction and cancer progression. Implications of 
      potential biological and clinical outcome for these signaling pathways are 
      presented. EXPERT OPINION: The CCN family member WISP1 and its intimate 
      relationship with canonical and non-canonical wingless signaling pathways of 
      PI3K, Akt1, beta-catenin and mTOR offer an exciting approach for governing the 
      pathways of apoptosis and autophagy especially in clinical disorders that are 
      currently without effective treatments. Future studies that can elucidate the 
      intricate role of these cytoprotective pathways during apoptosis and autophagy 
      can further the successful translation and development of these cellular targets 
      into robust and safe clinical therapeutic strategies.
FAU - Maiese, Kenneth
AU  - Maiese K
AD  - New Jersey Health Sciences University, Cancer Institute of New Jersey, Laboratory 
      of Cellular and Molecular Signaling, F 1220, 205 South Orange Avenue, Newark, New 
      Jersey 07101, USA. wntin75@yahoo.com
FAU - Chong, Zhao Zhong
AU  - Chong ZZ
FAU - Shang, Yan Chen
AU  - Shang YC
FAU - Wang, Shaohui
AU  - Wang S
LA  - eng
GR  - R01 NS053946/NS/NINDS NIH HHS/United States
GR  - NS059346-03S1/NS/NINDS NIH HHS/United States
GR  - NS059346-04/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120827
PL  - England
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
RN  - 0 (CCN Intercellular Signaling Proteins)
RN  - 0 (CCN4 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (beta Catenin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Apoptosis/*physiology
MH  - Autophagy/*physiology
MH  - CCN Intercellular Signaling Proteins/metabolism
MH  - Disease
MH  - Humans
MH  - Oxidative Stress
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - beta Catenin/metabolism
PMC - PMC3500415
MID - NIHMS404106
COIS- Declaration of interest The authors state no other conflicts of interest.
EDAT- 2012/08/29 06:00
MHDA- 2013/04/24 06:00
PMCR- 2013/12/01
CRDT- 2012/08/29 06:00
PHST- 2012/08/29 06:00 [entrez]
PHST- 2012/08/29 06:00 [pubmed]
PHST- 2013/04/24 06:00 [medline]
PHST- 2013/12/01 00:00 [pmc-release]
AID - 10.1517/14728222.2012.719499 [doi]
PST - ppublish
SO  - Expert Opin Ther Targets. 2012 Dec;16(12):1203-14. doi: 
      10.1517/14728222.2012.719499. Epub 2012 Aug 27.